Asimov
launched Chrysalis transposase in June 2026, a proprietary genome-integration tool engineered from butterfly species delivering stable expression across 60+ generations and clonal titers above 12 g/L,…
- Country
- United States
genetic-circuit-design
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaepamoa-china
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Intelligent genetic switches (kill switches) | genome-engineering | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.